Stemetix, Inc.
Needham, United States · Founded 2016
- Headquarters
- Needham, Massachusetts
- Employees
- 1–10
- Founded
- 2016
- Business Model
- B2B
About
Stemetix, Inc. is a Needham, Massachusetts biotechnology company focused on small-molecule drug development for neurological recovery following stroke and traumatic brain injury. The company discovered novel small molecules that bind to the FGF-2/receptor (FGFR1) complex and enhance FGF-2 signal transduction, promoting neurological recovery after ischemic stroke. Stemetix was founded by Seth Finklestein (CEO) and Ray Soumya, with scientific roots in research at Harvard/Massachusetts General Hospital. The company received HHS SBIR funding including a $1.35M grant in 2018. According to secondary sources, Stemetix is currently inactive (deadpooled).
Summary
Stemetix, Inc. is a Biotech company based in Needham, United States, founded in 2016.
Similar Companies
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intellig...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/stemetix-inc"><img src="https://indexed.vc/api/badge/company/stemetix-inc" alt="Stemetix, Inc. on Indexed.vc" width="260" height="76" /></a>